Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067677 | 0.92 | SIGMAR1 (0.71) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL28741993 | 0.88 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL4848450 | 0.88 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL9852459 | 0.86 | SIGMAR1 (0.75) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL5862113 | 0.86 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL6333442 | 0.85 | SIGMAR1 (0.73) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL21816604 | 0.85 | SIGMAR1 (0.73) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL3075354 | 0.85 | SIGMAR1 (0.81) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL29640480 | 0.85 | SIGMAR1 (0.81) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL5124505 | 0.85 | SIGMAR1 (0.81) | SIGMAR1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SIGMAR1 3888/4885POLB 1674/4885L3MBTL1 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.